Regulatory Update

DEA Timely Applicant Guidance Sets Supply Chain Requirements

October 30, 2026 | Vatic Global Advisors

On October 30, 2026, DEA posted DEA Medical Marijuana Timely Applicant Information on its Diversion Control Division website. The guidance explains what businesses that applied for registration under 21 CFR 1301.13(k) during the expedition period may do while their applications are pending, who they may buy from and sell to, and what records they are expected to keep. It also sets November 29, 2026 as the date by which DEA expects those businesses to have compliant supply chains in place.

DEA states that the guidance does not have the force and effect of law and is intended to clarify existing requirements. It is the first operational guidance DEA has issued for the medical marijuana registration program, and it changes how state licensed operators manage their trading relationships.

Who is a timely applicant

A timely applicant is a business that submitted a complete application, including payment of the registration fee, between April 28 and June 26, 2026. A business loses that status if it withdraws its application, if the Administrator issues a final order denying it, or if it lacks the required state medical marijuana license. Under 21 CFR 1301.13(k)(7), a timely applicant may continue dispensing, manufacturing, or distributing Schedule III medical marijuana under its state license while its application is pending, notwithstanding the general rule in 21 CFR 1301.13(a) that registered activity begins only when a registration is granted.

DEA posts a list of timely applicants on its Medical Marijuana Information page, identified by state, business activity, and control number. The list is updated as applicants are registered, withdraw, or lose timely status, and it does not include business names.

Who timely applicants may do business with

Timely applicants may conduct Schedule III medical marijuana activity with other timely applicants and with DEA registrants. A timely distributor may buy from a timely manufacturer and sell to a timely dispenser, and a registered dispensary may continue to receive product from a timely distributor.

Timely applicants and registrants may not conduct Schedule III medical marijuana activity with businesses that did not complete an application within the expedition period, or that have not applied at all, until those businesses are registered. DEA states that trading with such a business could be grounds for denying a timely applicant's application or revoking a registrant's certificate of registration.

Due diligence DEA expects

DEA describes the minimum due diligence for each trading partner during this transition.

  • For a timely dispenser, obtain a copy of its Marijuana Dispensary Information Submission confirmation and verify its document control number on the Diversion Control website.
  • For a timely manufacturer or distributor, obtain a copy of its DEA submission confirmation and verify its document control number.
  • For a DEA registrant, obtain a copy of its certificate of registration.
  • For every trading partner, obtain a copy of its state license and confirm that the license is active.
  • Keep records of all due diligence performed.

Records

The guidance states that registrants must keep all records required for Schedule III controlled substances under 21 CFR Part 1304, because the Administrator has concluded that all such records are necessary to comply with federal statutory and treaty obligations. Where a registrant transacts with a timely applicant, its records may show the applicant's document control number in place of a DEA registration number.

This is a significant clarification. Paragraph (k)(4) of 1301.13 directs DEA to require only the records necessary for statutory and treaty compliance and to accept state records to the maximum extent permissible. DEA has now stated that the full Part 1304 framework meets that standard. Registrants should plan to maintain federal inventories, receiving and distribution records, and the other Part 1304 records alongside their state tracking system.

Laboratory testing

Analytical laboratories are not covered by the interim authority in 1301.13(k)(7), so a laboratory must hold a DEA registration to handle Schedule III medical marijuana. Recognizing that few laboratories are registered, DEA states it does not intend to penalize registrants and timely applicants for sending de minimis quantities to an unregistered laboratory, provided the laboratory is in the same state and detailed records are kept.

That discretion applies only where using a DEA registered laboratory would violate state law, meaning either no laboratory anywhere in the United States is registered for this testing, or state law bars sending samples out of state and no laboratory in the operator's state is registered. It does not permit receiving product back from an unregistered laboratory.

Existing inventory and the November 29 date

Timely dispensers and distributors may continue to possess, dispense, and distribute inventory acquired before the guidance was issued, including inventory obtained from businesses that are not timely applicants or registrants. DEA expects timely applicants to verify the status of their trading partners and adjust their supply chains no later than November 29, 2026.

What this means for operators

Every timely applicant should now maintain a trading partner file. The file lists each supplier and customer, records whether each is a timely applicant or a registrant, holds the confirmation or certificate and the state license for each, and documents verification of each document control number. Relationships with businesses that did not apply within the expedition period will need to change, because those businesses cannot supply or purchase from a timely applicant until they are registered. Operators that send samples for state required testing should confirm whether their laboratory is registered and, where it is not, document why the DEA discretion applies.

Businesses that did not apply within the expedition period face a narrower market until they are registered, because timely applicants and registrants may not trade with them. For those businesses, a complete application and a well prepared inspection are the path into the federal supply chain. Our update on registration after the expedited window covers the current application process.

Discuss Your DEA Registration

We advise U.S. state medical cannabis operators on DEA registration, security, and recordkeeping requirements. Contact us to schedule a consultation.

Schedule a Consultation